Back to ABT Overview
NYQ · Valuation Lab
ABT
Abbott Laboratories
Last$105.71
Market cap182.9B
EV/EBITDA18.2x
Intrinsic value
$171.71
MoS +38.4% · Undervalued
Assuming 15.5% FCF margin and 13.0% Y1–5 growth.
Upside to price
EV (DCF)324.2B
Terminal share72%
Expected IV$184.26
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 72% of EV
PV of stage FCFs90.9B
PV of terminal value233.3B
Enterprise value324.2B
Net cash / (debt)-27.1B
Equity value297.1B
Intrinsic value / share$171.71
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 52.6B | 8.2B | 7.6B | 93.7% |
| Y2 | 59.5B | 9.2B | 8.1B | 87.9% |
| Y3 | 67.2B | 10.4B | 8.6B | 82.3% |
| Y4 | 76B | 11.8B | 9.1B | 77.2% |
| Y5 | 85.8B | 13.3B | 9.6B | 72.3% |
| Y6 | 91.4B | 14.2B | 9.6B | 67.8% |
| Y7 | 97.4B | 15.1B | 9.6B | 63.6% |
| Y8 | 103.7B | 16.1B | 9.6B | 59.6% |
| Y9 | 110.4B | 17.1B | 9.6B | 55.8% |
| Y10 | 117.6B | 18.2B | 9.5B | 52.3% |
| Terminal | — | — | 233.3B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.